[1]
Gowshall M, Taylor-Robinson SD. The increasing prevalence of non-communicable diseases in low-middle income countries: the view from Malawi. Int J Gen Med 2018; 11: 255-64.
[4]
Forbes JM, Fotheringham AK. Vascular complications in diabetes: old messages, new thoughts. Diabet Med 2017; 60: 2129-38.
[5]
Einarson TR, Acs A, Ludwig C, Panton UH. Economic burden of cardiovascular disease in type 2 diabetes: A systematic review. Value Health 2018; 21: 881-90.
[6]
Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115: 3213-23.
[7]
Zghebi SS, Steinke DT, Carr MJ, Rutter MK, Emsley RA, Ashcroft DM. Examining trends in type 2 diabetes incidence, prevalence and mortality in the UK between 2004 and 2014. Diabetes Obes Metab 2017; 19: 1537-45.
[8]
Rouyard T, Kent S, Baskerville R, Leal J, Gray A. Perceptions of risks for diabetes‐related complications in Type 2 diabetes populations: a systematic review. Diabet Med 2017; 34: 467-77.
[9]
Merz C, Buse J, Tuncer D, Twillman G. Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol 2002; 40: 1877-81.
[10]
Polyzos SA, Bugianesi E, Kountouras J, Mantzoros CS. Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists. Metabolism 2017; 66: 64-8.
[11]
Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother 2014; 15: 493-503.
[12]
Higgins LS, Mantzoros CS. The development of INT131 as a selective PPARgamma modulator: Approach to a safer insulin sensitizer. PPAR Res 2008; 2008936906
[13]
Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016; 150: 1147-59.
[14]
Lee YH, Kim JH, Kim SR, et al. Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness. J Korean Med Sci 2017; 32: 60-9.
[15]
Choung S, Joung KH, You BR, Park SK, Kim HJ, Ku BJ. Treatment with lobeglitazone attenuates hepatic steatosis in diet-induced obese mice. PPAR Res 2018; 20184292509
[16]
Gibbons CH, Goebel-Fabbri A. Microvascular complications associated with rapid improvements in glycemic control in diabetes. Curr Diab Rep 2017; 17(7): 48.
[17]
Doumas M, Imprialos K, Stavropoulos K, Reklou A, Sachinidis A, Athyros VG. Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints. Curr Pharm Des 2018; 24(17): 1879-86.
[18]
Jespersen MJ, Knop FK, Christensen M. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol 2013; 9: 17-29.
[19]
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-22.
[20]
Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173-81.
[21]
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.
[22]
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-34.
[23]
Lovic D, Piperidou A, Zografou I, et al. The growing epidemic of diabetes mellitus. Curr Vasc Pharmacol 2020; 18(2): 104-9.
[24]
Viigimaa M, Sachinidis A, Toumpourleka M, et al. Macrovascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol 2020; 18(2): 110-6.
[25]
Faselis C, Katsimardou A, Imprialos K, et al. Microvascular complications of type 2 diabetes. Curr Vasc Pharmacol 2020; 18(2): 117-24.
[26]
Patoulias D, Stavropoulos K, Imprialos K, et al. Pharmacological management of cardiac disease in patients with type 2 diabetes: insights into clinical practice. Curr Vasc Pharmacol 2020; 18(2): 125-38.
[27]
Papademetriou V, Alataki S, Stavropoulos K, et al. Pharmacological management of diabetic nephropathy. Curr Vasc Pharmacol 2020; 18(2): 139-47.
[28]
Didangellos T, Kantartzis K. Diabetes and heart failure: is it hyperglycemia or hyperinsulinemia? Curr Vasc Pharmacol 2020; 18(2): 148-57.
[29]
Didangelos T, Veves A. Treatment of diabetic cardiovascular autonomic, peripheral and painful neuropathy. Focus on the treatment of Cardiovascular Autonomic Neuropathy with ACE inhibitors. Curr Vasc Pharmacol 2020; 18(2): 158-71.
[30]
Alvaro-Afonso FJ, Garcia-Alvarez Y, Lazaro-Martinez JL, et al. Advances in dermoepidermal skin substitutes for diabetic foot ulcers. Curr Vasc Pharmacol 2020; 18(2): 182-92.
[31]
Athyros VG, Polyzos SA, Kountouras J, et al. Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block. Curr Vasc Pharmacol 2020; 18(2): 172-81.
